Skip to content

    Leukemia & Lymphoma

    Font Size
    A
    A
    A

    FDA Approves Imbruvica for Chronic Leukemia

    Drug inhibits enzyme that spurs cancer growth

    WebMD News from HealthDay

    By Scott Roberts

    HealthDay Reporter

    WEDNESDAY, Feb. 12, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval of Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have tried at least one other anti-cancer therapy.

    CLL progresses slowly, gradually leading to an increase in white blood cells called B lymphocytes. Last year, some 15,680 Americans were diagnosed with CLL and 4,580 died from it, the agency said Wednesday in a news release, citing the National Cancer Institute.

    Imbruvica was approved last November to treat people with mantle cell lymphoma.

    Approval for CLL was based on clinical studies involving 48 people, the FDA said. Some 58 percent of participants had their cancer shrink after treatment.

    Among the most common side effects of the drug were: low blood platelets, diarrhea, bruising, upper respiratory tract infection, fatigue and muscle pain.

    Imbruvica is manufactured by Pharmacyclics, based in Sunnyvale, Calif.

    Today on WebMD

    stem cells
    What are they and why do we need them?
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Do you know the symptoms?
     
    Vitamin D
    SLIDESHOW
    New Treatments For Non-Hodgkins Lymphoma
    FEATURE
     
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
    Pets Improve Your Health
    SLIDESHOW